Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer

Florian C. Gaertner1,*, Khalil Halabi1,*, Hojjat Ahmadzadehfar1, Stefan Kürpиг1, Elisabeth Eppard1, Charalambos Kotsikopoulos1, Nikolaos Liakos1, Ralph A. Bundschuh1, Holger Strunk2 and Markus Essler1

1Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
2Department of Radiology, University Hospital Bonn, Bonn, Germany
*These authors contributed equally to this work

Correspondence to: Florian C. Gaertner, email: florian.gaertner@ukbonn.de

Keywords: PSMA, PET/CT, radionuclide therapy, prostate cancer, tumor load

Received: November 10, 2016; Accepted: June 26, 2017; Published: July 06, 2017

ABSTRACT

Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load.

Results: In patients with high tumor load, SUV\textsubscript{mean} was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0.001). Further significant differences were observed for brain, mediastinum, liver, spleen and muscle. Total tracer retention was higher in patients with high tumor load (p < 0.05). SUV in lacrimal, salivary glands and kidneys correlated negatively with PSA.

Materials and Methods: 135 patients were retrospectively evaluated. SUV was measured in the lacrimal and salivary glands, brain, heart, liver, spleen, kidneys, muscle and bone. SUV was correlated with visual tumor load, total tracer retention and PSA.

Conclusions: Patients with high tumor load show a significant reduction of tracer uptake in dose-limiting organs. As similar effects might occur when performing RLT using Lu-177-labeled PSMA-ligands, individual adaptations of therapy protocols based on diagnostic PSMA PET imaging before therapy might help to further increase efficacy and safety of RLT.

INTRODUCTION

The prostate-specific membrane antigen (PSMA) is a promising target for prostate cancer diagnostics and therapy. Chelator-coupled PSMA-ligands based on the Glu-urea-Lys motif suitable for nuclear medicine applications have been developed, e.g. PSMA-11 and PSMA-617 [1–4]. Due to the frequent high expression of PSMA on the surface of prostate cancer cells, which correlates with androgen independence, metastasis and disease progression [5], these compounds rapidly accumulate in prostate cancer lesions. Labeling with the positron-emitter Ga-68 facilitates PET imaging for detection of prostate cancer lesions [6] and labeling with the beta-emitting radionuclide Lu-177 enables PSMA-targeted radionuclide therapy. First results with Lu-177-labeled PSMA-617 already indicate good response rates with low short-term side-effects in patients with advanced, castrate-resistant, metastasized prostate cancer [7–13]. Accumulation of PSMA-ligands is also observed in non-tumorous normal tissues, such as liver, spleen, kidneys and salivary glands. Especially the salivary glands and the kidneys are regarded as dose limiting organs when performing PSMA-targeted radionuclide therapy.
The total tumor mass might affect uptake in dose-limiting normal organs due to a tumor steal effect. It is currently unknown if a tumor steal effect is applicable to PSMA-targeting radiotracers and to what extent it affects the biodistribution of the radiopharmaceutical in normal tissues. However, knowledge of these effects is fundamental for estimation of maximum tolerated activities and optimization of clinical radionuclide therapy protocols.

In the current study, we retrospectively analyzed uptake of the radiolabeled PSMA-ligand Ga-68-PSMA-11 in normal tissues in relation to tumor load in patients who underwent PET/CT for staging of prostate cancer.

RESULTS

Patient characteristics

A total of 135 patients undergoing Ga-68-PSMA-11 PET/CT were retrospectively evaluated. Primary indications for referral were staging of prostate cancer and evaluation for Lu-177-PSMA-617 therapy. Mean patient age was 71.8 ± 7.4 years (range 42–94 years), mean administered activity was 158 ± 30 MBq (range 105–261 MBq). Patients with low administered activities (< 100 MBq) were excluded from analysis. Mean incubation time was 89 ± 22 minutes (range 48–143 minutes). Mean PSA was 188.0 ± 412 ng/ml (range 0.02–2860 ng/ml). There were no adverse or clinically detectable pharmacologic effects in any of the 135 subjects.

As the diagnostic PET/CT scans did not include the area above the skull base, the parotid glands, lacrimal and salivary glands and brain were not in the field of view in 16 patients. Due to extensive bone metastases, normal bone SUV could not be evaluated in 37 patients. 2 patients had prior splenectomy preventing spleen SUV measurement. In 2 patients, only one kidney was evaluated due to functional impairment of the contralateral kidney. In 12 patients, the sublingual glands could not be delineated due to low uptake. In 8 patients one or both submandibular glands could not be delineated due to low uptake.

Tumor load

82 patients were rated as low tumor load, 19 as medium tumor load and 34 as high tumor load. Examples are shown in Figure 1.

Tracer uptake in the lacrimal and salivary glands was highly dependent on tumor load, showing a significant reduction in patients with high tumor burden to values between 58% and 64% (p < 0.001), a graphical representation is shown in Figure 2A and detailed results are listed in Table 1. Tracer uptake in the kidneys was reduced to 58% (SUV max) and 55% (SUV mean), see Figure 2B.

The effects of tumor load on tracer uptake in other normal organs was less pronounced, in the spleen tracer uptake was reduced to values from 83% to 81%, in the liver from 82% to 75% and in the brain from 83% to 70% (p < 0.05). SUV max in the mediastinum and muscle showed only a slight, but significant reduction to 92% and 83%, respectively (p < 0.05). No significant differences were observed for uptake in normal bone (Figure 2C, Table 1).

Retention index (RI%)

Patients categorized as low tumor load (n = 82) showed a total tracer retention of 70.7% ± 7.4%. The results of patients with medium tumor load were not significantly different (71.0% ± 8.8%, p > 0.05, n = 19). A slightly higher tracer retention was observed in patients with high tumor load (74.0% ± 7.6%, p < 0.05, n = 34).

There was a slight, but significant negative correlation of RI% and uptake in the lacrimal, parotid and submandibular glands. No significant correlation was observed for sublingual gland and kidney uptake (Table 2).

PSA

Serum PSA was available for 133 of 135 patients. Mean PSA in patients categorized as low tumor load (n = 80) was 25.3 ± 69.0 ng/ml. In patients with medium tumor load (n = 19), mean PSA was significantly higher (298 ± 299 ng/ml, p < 0.001). Also, patients with high tumor load (n = 34) showed a significantly higher PSA than patients with low tumor load (509 ± 663 ng/ml, p < 0.001).

There were significant negative correlations of serum PSA and uptake in the lacrimal and salivary glands, as well as in the kidneys, however the correlation coefficients were only in the moderate range, see Table 2 and Figure 3.

A significant (p < 0.05) reduction of mean SUV in the salivary glands and kidneys was observed at PSA thresholds of 6–9 ng/ml and above, and a reduction of more than one standard deviation was mostly observed at PSA thresholds above 500–900 ng/ml (see Table 3).

Incubation time and injected activity

Significant correlations (p < 0.05) between incubation time and uptake were only observed for SUV mean with very low correlation coefficients in the mediastinum (rho = −0.209) and in the spleen (rho = −0.213). No significant correlations were observed for SUV mean in all other organs tested and for SUV max in all organs (p > 0.05).

Significant correlations (p < 0.05) between injected activity and uptake were observed with very low correlation coefficients for SUV mean in the lacrimal glands (rho = 0.199), and for SUV max in the lacrimal glands (rho = 0.231), in the kidneys (rho = 0.120) and in the bone (rho = 0.172). No significant correlations were observed for SUV mean or SUV max in all other organs tested (p > 0.05).
**Gleason score and age**

Gleason score was available for 107 of 135 patients. Most patients referred for Ga-68-PSMA-11 PET/CT had a Gleason score between 6 and 9 (104 patients), with only 2 patients showing a Gleason score of 10 and one patient with an initial Gleason score of 4. There was a trend of patients with a higher Gleason score to present with a higher tumor load. In the group of patients with low tumor load, the median Gleason score was 7, and patients with medium and high tumor load had a median Gleason score of 8 and 9, respectively.

There was a tendency of a higher tumor load to be present with increasing age. The mean patient age in the group with low tumor load was 70.4 ± 7.3 years, whereas the values for medium and high tumor load were 73.4 ± 6.5 years and 74.3 ± 7.8 years, respectively. The age difference between the low and high tumor load groups was significantly different ($p < 0.05$).

**DISCUSSION**

We observed a pronounced influence of tumor load on the biodistribution of radiolabeled PSMA-ligands in normal tissues. A mean reduction of activity concentration by almost 50% was observed in some organs in patients with high tumor load, in individual cases markedly exceeding 50% reduction. Especially, a high dependence of tracer uptake on tumor load was observed in the kidneys, as well as in the salivary glands and lacrimal glands. These organs exhibit high physiological uptake of radiolabeled PSMA-ligands and are therefore considered dose-limiting organs when performing radionuclide therapy using Lu-177-labeled PSMA-binding constructs [12].

For external beam radiotherapy of the kidneys, a tolerance dose of 23 Gy is widely accepted [14]. Regarding the salivary glands, Deasy et al. reported that severe xerostomia can usually be avoided if the absorbed dose in both parotid glands is limited to 25 Gy [15].

![Figure 1: Examples of Ga-68-PSMA-11 PET/CT examinations (MIP projections, SUV 0–12) in patients with low, medium and high tumor load.](image)

| Tumor load: | low | medium | high |
|-------------|-----|--------|------|
| PSA:        | 4.8 ng/ml | 454 ng/ml | 2860 ng/ml |
| Gleason:    | 7   | 8      | 9    |
| RI%:        | 63.6 % | 70.8 % | 75.0 % |
a study with 7 patients undergoing therapy with Lu-177-PSMA-617, Kabasakal et al. estimated a mean absorbed dose in the parotid glands of 1.17 Gy / GBq and in the kidneys of 0.88 Gy/GBq [16]. They reported a high inter-patient variability for absorbed doses, which is in line with our current results that additionally point to a significant

| Tumor load | N | SUV_{max} ± SD | % of low | p to low | SUV_{mean} ± SD | % of low | p to low |
|------------|---|----------------|----------|----------|-----------------|----------|----------|
| Lacrimal glands | Low | 136 | 7.55 ± 3.32 | - | - | 4.77 ± 2.02 | - | - |
| Medium | 34 | 4.76 ± 1.46 | 63.1% | < 0.001 | 2.85 ± 0.99 | 59.7% | < 0.001 |
| High | 67 | 4.81 ± 2.47 | 63.7% | < 0.001 | 2.94 ± 1.57 | 61.5% | < 0.001 |
| Parotid glands | Low | 146 | 18.24 ± 4.60 | - | - | 11.69 ± 3.03 | - | - |
| Medium | 36 | 13.00 ± 4.00 | 71.3% | < 0.001 | 8.02 ± 2.47 | 68.6% | < 0.001 |
| High | 67 | 10.60 ± 3.41 | 58.1% | < 0.001 | 6.62 ± 2.09 | 56.6% | < 0.001 |
| Submandibular glands | Low | 161 | 20.29 ± 5.21 | - | - | 12.93 ± 3.40 | - | - |
| Medium | 36 | 13.92 ± 4.89 | 68.6% | < 0.001 | 8.46 ± 2.99 | 65.4% | < 0.001 |
| High | 62 | 13.06 ± 4.73 | 64.4% | < 0.001 | 8.24 ± 3.06 | 63.7% | < 0.001 |
| Sublingual glands | Low | 80 | 7.05 ± 3.12 | - | - | 4.15 ± 1.62 | - | - |
| Medium | 15 | 4.36 ± 1.86 | 61.9% | < 0.05 | 2.55 ± 1.12 | 61.5% | < 0.001 |
| High | 28 | 4.22 ± 2.39 | 59.8% | < 0.001 | 2.54 ± 1.24 | 56.6% | < 0.001 |
| Kidneys | Low | 162 | 50.2 ± 15.55 | - | - | 29.9 ± 9.59 | - | - |
| Medium | 38 | 43.1 ± 10.27 | 85.9% | < 0.05 | 24.4 ± 6.91 | 81.6% | < 0.001 |
| High | 68 | 29.2 ± 11.10 | 58.3% | < 0.001 | 16.6 ± 6.72 | 55.4% | < 0.001 |
| Spleen | Low | 82 | 9.97 ± 3.53 | - | - | 6.95 ± 2.92 | - | - |
| Medium | 18 | 9.26 ± 3.28 | 92.9% | > 0.05 | 6.47 ± 2.76 | 93.1% | > 0.05 |
| High | 33 | 8.28 ± 4.03 | 83.1% | < 0.05 | 5.66 ± 3.23 | 81.4% | < 0.05 |
| Liver | Low | 81 | 7.58 ± 1.91 | - | - | 4.34 ± 1.33 | - | - |
| Medium | 19 | 7.26 ± 1.75 | 95.8% | > 0.05 | 4.19 ± 1.19 | 96.6% | > 0.05 |
| High | 32 | 6.19 ± 1.50 | 81.7% | < 0.05 | 3.27 ± 0.81 | 75.4% | < 0.001 |
| Mediastinum | Low | 82 | 2.99 ± 0.61 | - | - | 1.06 ± 0.19 | - | - |
| Medium | 19 | 3.25 ± 0.82 | 108.7% | > 0.05 | 1.06 ± 0.21 | 100.4% | > 0.05 |
| High | 34 | 2.87 ± 1.07 | 96.0% | > 0.05 | 0.97 ± 0.29 | 91.9% | < 0.05 |
| Bone | Low | 163 | 2.50 ± 0.92 | - | - | 0.91 ± 0.39 | - | - |
| Medium | 11 | 2.67 ± 1.73 | 106.9% | > 0.05 | 0.88 ± 0.52 | 96.0% | > 0.05 |
| High | 10 | 2.75 ± 1.47 | 110.2% | > 0.05 | 0.79 ± 0.41 | 86.0% | > 0.05 |
| Muscle | Low | 82 | 1.27 ± 0.28 | - | - | 0.39 ± 0.09 | - | - |
| Medium | 18 | 1.30 ± 0.35 | 102.3% | > 0.05 | 0.35 ± 0.07 | 89.5% | < 0.05 |
| High | 34 | 1.32 ± 0.81 | 103.7% | > 0.05 | 0.33 ± 0.20 | 82.7% | < 0.001 |
| Brain | Low | 68 | 0.78 ± 0.26 | - | - | 0.18 ± 0.07 | - | - |
| Medium | 17 | 0.66 ± 0.23 | 84.5% | > 0.05 | 0.14 ± 0.06 | 80.7% | > 0.05 |
| High | 34 | 0.64 ± 0.26 | 82.7% | < 0.05 | 0.12 ± 0.06 | 70.0% | < 0.001 |

Legend: The Wilcoxon-Mann-Whitney test was used to test for significance of uptake reduction in patients with medium and high tumor load compared to patients with low tumor load. Significant p-values (< 0.05) are highlighted by bold face type.
dependence of radiotracer uptake on tumor load. For the same compound, similar values were reported by Delker et al. with 1.4 Gy/GBq for the salivary glands and 0.6 Gy/GBq for the kidneys in 5 patients (2 cycles of therapy each) [17], and by Kratochwil et al. with 1.4 Gy/GBq for the salivary glands and 0.75 Gy/GBq for the kidneys [18]. Regarding another PSMA-ligand, Lu-177-DOTAGA-(I-y) fk (Sub-KuE), the parotid dose was reported as 1.3 Gy/GBq and the kidney dose was 0.8 Gy/GBq [19]. Regarding Lu-177-PSMA-I&T, the parotid dose was 0.55 Gy/GBq and the dose to the kidneys was reported as 0.72 Gy/GBq [20]. Extrapolating from these data, a mean absorbed dose of 23 Gy in the kidneys would be reached by a cumulative activity of 26–38 GBq Lu-177-PSMA-ligand. For the parotid glands, a mean absorbed dose of 25 Gy would be reached by the application of a cumulative activity of 18–45 GBq Lu-177-PSMA-ligand. These cumulative activities are in the range of currently discussed clinical therapy protocols for radionuclide therapy using Lu-177-labeled PSMA-ligands.

Our current results indicate that patients with high tumor load might tolerate significantly higher activity amounts of Lu-177-labeled PSMA-ligands before adverse effects on kidney and salivary gland function become

Figure 2: Reduction of Ga-68-PSMA-11 uptake in normal organs dependent on tumor load. Bars represent mean uptake of Ga-68-PSMA-11 (SUV$_{mean}$), error bars represent ± ½ SD. (A) In the lacrimal and salivary glands, a highly significant reduction in tracer uptake was observed in the groups of patients with medium and high tumor load. (B) Also in the kidneys, tracer uptake was markedly decreased in patients with medium and high tumor load with high significance. (C) Regarding the remaining normal tissues evaluated, patients with high tumor load showed significantly reduced tracer uptake in the brain, mediastinal blood pool, liver, spleen and muscle, however the amount of uptake reduction was less pronounced compared to the lacrimal/salivary glands and the kidneys. No significant differences were observed for bone uptake. *marks significant differences to the low tumor load group ($p < 0.05$). **marks highly significant differences to the low tumor load group ($p < 0.001$).
However, the restriction to single static scans is a limitation of our study. A dosimetry study with several intra-individual time points is needed to confirm these results.

Kratochwil et al. performed a dosimetry study with Lu-177-PSMA-617 in 4 patients (2 cycles of therapy per patient), however they did not observe a dependency of salivary gland or kidney dose on tumor burden, which however might be attributable to the small number of patients evaluated [18].

Though a fraction of the patients in our collective subsequently underwent Lu-177-PSMA-617 therapy in the further clinical course, the number of patients is not sufficient to assess if a correlation exists between pre-therapeutic salivary gland uptake and the occurrence of post-therapeutic xerostomia. To evaluate this, a prospective clinical trial including a higher number of patients is needed.

Furthermore, even when taking tumor load into account, inter-patient variability of tracer uptake in the kidneys and salivary glands remains high. Thus, incorporating a patient’s individual biodistribution data, not only based on visual evaluation of tumor load and/or serum PSA measurement, but additionally on kidney and Table 2: Correlation of Ga-68-PSMA-11 uptake with retention index and serum PSA

|                      | Correlation of RI% with SUV | Correlation of PSA with SUV |
|----------------------|-----------------------------|-----------------------------|
|                      | $N$  | $SUV_{\text{max}}$ | rho ($p^a$) | $SUV_{\text{mean}}$ | rho ($p^a$) | $N$  | $SUV_{\text{max}}$ | rho ($p^a$) | $SUV_{\text{mean}}$ | rho ($p^a$) |
| Lacrimal glands      | 237  | -0.277 (< 0.001$^b$) | -0.263 (< 0.001$^b$) | 235  | -0.346 (< 0.001$^b$) | -0.398 (< 0.001$^b$) |
| Parotid glands       | 249  | -0.169 (< 0.05$^b$)  | -0.158 (< 0.05$^b$)  | 247  | -0.551 (< 0.001$^b$) | -0.569 (< 0.001$^b$) |
| Submandibular glands | 259  | -0.129 (< 0.05$^b$)  | -0.144 (< 0.05$^b$)  | 257  | -0.412 (< 0.001$^b$) | -0.448 (< 0.001$^b$) |
| Sublingual glands    | 123  | 0.000 (> 0.1)       | -0.048 (> 0.1)       | 121  | -0.376 (< 0.001$^b$) | -0.374 (< 0.001$^b$) |
| Kidneys              | 268  | 0.062 (> 0.1)       | 0.063 (> 0.1)        | 266  | -0.487 (< 0.001$^b$) | -0.517 (< 0.001$^b$) |

Legend: Correlation coefficients (Spearman’s rho) of Ga-68-PSMA-11 uptake ($SUV_{\text{max}}$ and $SUV_{\text{mean}}$) with retention index (RI%, left side of the table) and serum PSA (right side of table) regarding the lacrimal and salivary glands and the kidneys. Low negative correlation coefficients were observed for correlation of $SUV$ with RI% for the lacrimal, parotid and submandibular glands. More pronounced negative correlations were observed for correlation of $SUV$ with serum PSA.

$^a$two-tailed.

$^b$marks significant correlations ($p < 0.05$).

Table 3: PSA thresholds for significant reduction of Ga-68-PSMA-11 uptake

|                      | $SUV_{\text{max}}$ | $SUV_{\text{mean}}$ |
|----------------------|---------------------|---------------------|
|                      | significant reduction if PSA | reduction > 1 SD if PSA | significant reduction if PSA | reduction > 1 SD if PSA |
| Lacrimal glands      | > 9 ng/ml           | N/A                 | > 8 ng/ml           | N/A                 |
| Parotid glands       | > 7 ng/ml           | > 500 ng/ml         | > 6 ng/ml           | > 500 ng/ml         |
| Submandibular glands | > 7 ng/ml           | > 500 ng/ml         | > 7 ng/ml           | > 500 ng/ml         |
| Sublingual glands    | > 6 ng/ml           | > 900 ng/ml         | > 7 ng/ml           | > 900 ng/ml         |
| Kidneys              | > 6 ng/ml           | > 800 ng/ml         | > 6 ng/ml           | > 800 ng/ml         |

Legend: When calculating mean SUV of potential dose-limiting organs in patients with serum PSA above a certain threshold, a significant reduction ($p < 0.05$) in comparison to all patients was observed at PSA thresholds above 6–9 ng/ml for $SUV_{\text{max}}$ and $SUV_{\text{mean}}$. Reduction of mean SUV of more than one standard deviation was observed at PSA levels above 500–900 ng/ml.

relevant. However, the restriction to single static scans is a limitation of our study. A dosimetry study with several intra-individual time points is needed to confirm these results.

Kratochwil et al. performed a dosimetry study with Lu-177-PSMA-617 in 4 patients (2 cycles of therapy per patient), however they did not observe a dependency of salivary gland or kidney dose on tumor burden, which however might be attributable to the small number of patients evaluated [18].

Though a fraction of the patients in our collective subsequently underwent Lu-177-PSMA-617 therapy in the further clinical course, the number of patients is not sufficient to assess if a correlation exists between pre-therapeutic salivary gland uptake and the occurrence of post-therapeutic xerostomia. To evaluate this, a prospective clinical trial including a higher number of patients is needed.

Furthermore, even when taking tumor load into account, inter-patient variability of tracer uptake in the kidneys and salivary glands remains high. Thus, incorporating a patient’s individual biodistribution data, not only based on visual evaluation of tumor load and/or serum PSA measurement, but additionally on kidney and
salivary gland uptake in diagnostic PSMA PET imaging before therapy or even by performing pre-therapeutic dosimetry seems rational for individual therapy planning to further optimize the efficacy of PSMA-targeted radionuclide therapy. Individual adaptations of therapy protocols might result in increased number of therapy cycles and/or increased activity amount per cycle in patients with low kidney and salivary gland uptake. Also, variable amounts of activity per cycle might be discussed, with higher amounts being applied during the first cycles, to account for decreasing tumor load during the course of radionuclide therapy.

Patients with high tumor load showed a slightly, yet significantly higher tracer retention in the body trunk than patients with low tumor load. This corroborates the hypothesis that extensive tumor uptake leads to less radiotracer being available for uptake in background organs, reducing accumulation in these organs, in terms of a tumor steal effect. However, as the retention index is only slightly elevated in patients with high tumor load and the correlation with tracer uptake yields only low correlation coefficients, this parameter does not seem feasible for quantitation of tumor load.

It is a limitation of our study that a systematic error in calculation of the retention index is present as the PET acquisitions did not include the lower extremities, and in some cases where a diagnostic CT protocol was performed additionally excluded the neurocranium, thus there is a tendency for underestimation of the retention index. However, as potential tracer accumulation in the head and legs is minimal compared to the body trunk, the estimated error is low and in our opinion negligible. Nevertheless, as distant metastases of prostate cancer may occur as singular metastases of lower legs, whole body acquisition of PSMA-PET should be considered in clinical imaging protocols.

The nasal mucosa, which sometimes shows accumulation of PSMA-ligands, has not been included in our evaluation. However, per Hohberg et al., absorbed organ doses of Lu-177-PSMA-therapy are not likely to be critical for the nasal mucous membrane, as typical therapy protocols result in a dose of about 7 Gy to the nasal mucosa, whereas the commonly applied dose constraint to this organ is 37 Gy [21].

Another limitation of our study are the variations in injected activity and incubation time, which might

Figure 3: Correlation of Ga-68-PSMA-11 uptake in normal organs (SUV_{mean}) with serum PSA as a surrogate of tumor load. Highly significant (p < 0.001) negative correlations were observed for the lacrimal glands, salivary glands and the kidneys, however the correlation coefficients (Spearman’s rho) were only in a moderate range, indicating a remaining high variability of tracer uptake.
PET emission data was acquired in 3D mode, emission scanner (Siemens Medical Solutions, Erlangen, Germany). The average dose was 158 ± 30 MBq (range 105–261 MBq). PET/CT was performed on a Biograph 2 PET/CT scanner (Siemens Medical Solutions, Erlangen, Germany). The retention index (RI%) was calculated by placing a rectangular VOI over the whole PET data set to measure total activity in the body trunk (MBq). Urinary bladder contents were delineated visually to determine total bladder activity (MBq), which was then subtracted from the total body trunk activity. The resulting difference, representing total activity remaining in body tissues at the time of PET imaging (MBq) was corrected for physical decay to the time point of tracer injection and additionally normalized to the injected activity. Therefore, RI% represents the percentage of radiotracer remaining in the body after the incubation period.

Tumor load was analyzed visually to categorize the patients into three groups: low, medium and high tumor load. Patients with disseminated bone metastases (> 30 single lesions or diffusely confluent bone lesions of uptake with incubation time were observed for SUVmean in the mediastinum and in the spleen with very low correlation coefficients (rho ≈ −0.2). When testing for correlations between injected activity and uptake, significant correlations were observed in the lacrimal glands, kidneys and in the bone, but again with only very low correlation coefficients (rho ≈ 0.1 to 0.2). To exclude a relevant influence of these parameters on the result of this study, we tested for dependencies of tumor load (PSA) with incubation time and injected activity. There were no significant correlations between tumor load and incubation time (p > 0.05) or between tumor load and injected activity (p > 0.05). Therefore, due to the low correlation coefficients, as well as to the missing dependencies of incubation time and injected activity on tumor load, a relevant influence of these parameters on the general result of this study can be excluded.

A significant reduction of mean tracer uptake in the salivary glands and kidneys was observed already at PSA levels above 6–9 ng/ml, and pronounced mean reductions in tracer accumulation of more than one standard deviation were observed when PSA was above 500–900 ng/ml. These calculations furthermore illustrate the reciprocal dependency of salivary gland and kidney uptake on tumor load. Nevertheless, even when taking tumor load and/or serum PSA into account, a pronounced variability of salivary gland and kidney uptake remains evident. Therefore, these values should not be regarded as cut-off thresholds for clinical decision making. Instead, the patient’s individual biodistribution in the target organs derived from diagnostic PSMA PET imaging before therapy appears to provide a more reliable basis for individual planning of PSMA-targeted radionuclide therapy.
encompassing more than half of the skeleton) showing intense uptake were defined as high tumor load. Patients with disseminated bone metastases showing only faint uptake or encompassing less than half of the skeleton, extensive PSMA-ligand accumulating lymph node bulks on both sides of the mediastinum or extensive PSMA-positive lung metastases were classified as medium tumor load. All other patients were classified as low tumor load.

**Statistics**

The Wilcoxon-Mann-Whitney test was used to test for reduction of tracer uptake in the patient groups based on tumor load. \( p < 0.05 \) was rated as significant and \( p < 0.001 \) as highly significant. Correlation of SUV with PSA and RI% were evaluated by calculating the correlation coefficient (Spearman’s rho) with a two-tailed test for significance.

**Abbreviations**

MIP: maximum intensity projection; OSEM: ordered subset expectation maximization; PET: positron emission tomography; PSA: prostate specific antigen; PSMA: prostate specific membrane antigen; RI%: retention index; SD: standard deviation; SUV: standardized uptake value; VOI: volume of interest.

**Authors’ contributions**

Study conception and design: FCG, KH, HA, RAB, ME. Data acquisition, analysis and interpretation: FCG, KH, HA, SK, EE, CK, NL, HS. Research supervision: HS, ME. Wrote the paper: FCG, KH. Revision and approval of the final content of the manuscript: FCG, KH, HA, SK, EE, CK, NL, RAB, HS, ME.

**ACKNOWLEDGMENTS**

We are grateful to all technicians at the PET unit who performed the patient scans. We would like to acknowledge the contributions of Michael Meisenheimer for the synthesis of Ga-68-PSMA.

**CONFLICTS OF INTEREST**

RAB has a non-commercial research contract with and has received a speaker honorarium from Mediso Medical Imaging Systems Ltd., Budapest, Hungary. ME is a consultant to Bayer, Novartis, Eisai and Ipsen.

**FUNDING**

EE received a research grant from the University Hospital Bonn, Germany (BONFOR 2015-1-03).

**REFERENCES**

1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labellabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. J Nucl Med Mol Imaging. 2013; 40:486–95. https://doi.org/10.1007/s00259-012-2298-2.

2. Benešová M, Schäfer M, Baader-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015; 56:914–20. https://doi.org/10.2967/jnumed.114.147413.

3. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, Kopka K, Haberkorn U. [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Mol Imaging. 2015; 42:987–8. https://doi.org/10.1007/s00259-014-2978-1.

4. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69:6932–40. https://doi.org/10.1158/0008-5472.CAN-09-1682.

5. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014; 28:555–63.

6. Rahbar K, Weckesser M, Huss S, Semjonov A, Breyholz HJ, Schrader AJ, Schäfers M, Bögemann M. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med. 2016; 57: 563–7. https://doi.org/10.2967/jnumed.115.169243.

7. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Bartenstein P, Pfestroff A, Lützen U, Marx M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017; 58:85–90. https://doi.org/10.2967/jnumed.116.183194.

8. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med. 2016; 57:1334–8. https://doi.org/10.2967/jnumed.116.173757.
9. Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H. Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. Clin Nucl Med. 2016; 41:478–80. https://doi.org/10.1097/RLU.0000000000001195.

10. Schlenkhoff CD, Knüpfer E, Essler M, Ahmadzadehfar H. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617. Clin Nucl Med. 2016; 41:572–3. https://doi.org/10.1097/RLU.0000000000001200.

11. Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M, Essler M. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5:114. https://doi.org/10.1186/s13550-015-0114-2.

12. Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärnter F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7:12477–88. https://doi.org/10.18632/oncotarget.7245.

13. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bögemann M. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Clin Nucl Med. 2016; 41:522–8. https://doi.org/10.1097/RLU.0000000000001240.

14. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21:109–22.

15. Deasy JO, Moisenenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010; 76:S58–63. https://doi.org/10.1016/j.ijrobp.2009.06.090.

16. Kahasakal L, AbuQbeita M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:1976–83. https://doi.org/10.1007/s00259-015-3125-3.

17. Delker A, Fendler WP, Kratochwil C, Brunegräf A, Gosewisch A, Gildehaus FJ, Tritscher S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böging D. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016; 43:42–51. https://doi.org/10.1007/s00259-015-3174-7.

18. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afşar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-Targeted Radiouclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57:1170–6. https://doi.org/10.2967/jnumed.115.171397.

19. Baum RP, Kulka MR, Schuchardt C, Singh A, Wirtz M, Wiesalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016; 57:1006–13. https://doi.org/10.2967/jnumed.115.168443.

20. Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendldecker WP, Herrmann K, Pföb CH, et al. Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017; 58:445–50. https://doi.org/10.2967/jnumed.116.178483.

21. Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, Drzezga A, Wild M. Lacrimal Glands May Represent Organs at Risk for Radioligand Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016; 18:437–45. https://doi.org/10.1007/s11307-016-0942-0.

22. Eppard E, Wuttke M, Nicodemus PL, Rösch F. Ethanol-based post-processing of generator-derived 68Ga toward kit-type preparation of 68Ga-radiopharmaceuticals. J Nucl Med. 2014; 55:1023–8. https://doi.org/10.2967/jnumed.113.133041.